The biggest investor in a nursing home chain can run but not hide from comeuppance for the chain’s alleged role in harms—including deaths—done to hundreds of patients.
Cytokinetics has secured FDA approval for aficamten, its new drug for the treatment of symptomatic obstructive HCM. Aficamten will be sold under the brand name Myqorzo.
PAD in patients with diabetes is common and associated with an increased risk of several adverse events. A new guidance from the American College of Cardiology reviewed this topic at length, identifying areas where care needs to improve.
One of the event's primary takeaways was that interventional cardiology does still attract a healthy number of trainees. However, SCAI sees several ways the specialty can improve to be even more appealing in the future.
PFA has emerged as the preferred ablation strategy for many electrophysiologists, but some questions do remain about its long-term impact. HRS is developing this new registry to be as user-friendly for clinicians as possible.
The ACC and AHA both issued new statements on noninvasive CCTA offerings that use advanced AI to evaluate patients with suspected CAD. These technologies have gained significant momentum in recent years, and experts agree that they represent a game-changing advancement in the world of cardiovascular imaging.
Ivenia ABUS Premium was designed to help streamline the supplemental breast ultrasound workloads and enhance diagnoses by improving ease of use and image reproducibility.
Using a left radial artery approach in the cath lab exposes interventional cardiologists to significantly less radiation than a hyper-adducted right radial artery approach. The difference is substantial enough for researchers to declare LRA "the primary access site for cardiac catheterization."
S. Chris Malaisrie, MD, professor of surgery at Northwestern University, explained what these data can tell us about the lifetime management of patients who require aortic valve replacement.
There are no standards requiring radiologists to report on the presence of BACs, even though up to half of referring providers have indicated they would prefer to be made aware of the finding.
The biggest investor in a nursing home chain can run but not hide from comeuppance for the chain’s alleged role in harms—including deaths—done to hundreds of patients.
Cytokinetics has secured FDA approval for aficamten, its new drug for the treatment of symptomatic obstructive HCM. Aficamten will be sold under the brand name Myqorzo.
PAD in patients with diabetes is common and associated with an increased risk of several adverse events. A new guidance from the American College of Cardiology reviewed this topic at length, identifying areas where care needs to improve.
